)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kuros Biosciences
Kuros Biosciences (KURN) investor relations material
Kuros Biosciences Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary15 Oct, 2026
Executive summary
9M 2026 medical device sales rose 40% YoY to $141.8m; FY 2026 guidance raised to 36%–40% sales growth and adjusted EBITDA margin above 14.5%.
Adjusted EBITDA increased 68% to $20.6m, with margin expanding to 14.5%; cash was $19.6m, ahead of plan.
Financial highlights
Total Group EBITDA rose 81% YoY to $13.5m in 9M 2026, from $7.4m.
Adjusted EBITDA increased 68% YoY to $20.6m, versus $12.2m; adjusted margin was 14.5%, up from 12.1%.
Cash position was $19.6m, up from $9.7m at June 30, 2026, and ahead of plan.
Outlook and guidance
FY 2026 sales growth guidance raised to 36%–40%; adjusted EBITDA margin expected to exceed 14.5%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kuros Biosciences
- 45% revenue growth and return to profitability in H1 2026, with strong outlook reaffirmed.KURN
Q2 2026 - Record profitability and clinical leadership drive expansion into spine, foot & ankle, and trauma.KURNCMD 2026
- Q1 2026 sales jumped 51% with robust Magnetos adoption and improved EBITDA margins.KURNQ1 2026 TU
- Record 72% revenue growth and first net profit in 2025, with strong outlook for 2026 expansion.KURNH2 2025
- Revenue up 77% year-over-year, 2025 sales guidance raised to at least 70% growth.KURNQ3 2025 TU
- 78% revenue growth, first operating profit, and global expansion drive robust outlook.KURNH1 2025
- 148% revenue growth and 12.5% EBITDA margin signal strong H1 and positive outlook.KURNH1 2024
- MagnetOs drives rapid growth with superior clinical data, global expansion, and operational excellence.KURNCMD 2025
- Record MagnetOs sales, profitability, and global expansion drive robust growth outlook.KURNH2 2024
Next Kuros Biosciences earnings date
H2 20263 Mar, 2027
Kuros Biosciences
Next Kuros Biosciences earnings date
H2 20263 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kuros Biosciences AG, operating under the ticker KURN, is a biotechnology company dedicated to discovering, developing, and delivering innovative fusion technologies for bone grafting. Founded as a spin-off from the Swiss Federal Institute of Technology in Zurich in 2000, Kuros Biosciences has established a significant presence in the field of tissue repair and regeneration. The company's flagship product line, MagnetOs, is designed for applications in spinal fusion, trauma, fracture repair, and as surgical sealants. The company is headquartered in Zurich, Switzerland, and its shares are listed on SIX.